Cayman
Showing 7951–8100 of 45550 results
-
AAPH is a water-soluble azo compound which is used extensively as a free radical generator, often in the study of lipid peroxidation and the characterization of antioxidants.{6422,7745,9407,9459} Decomposition of AAPH produces molecular nitrogen and 2 carbon radicals. The carbon radicals may combine to produce stable products or react with molecular oxygen to give peroxyl radicals. The half-life of AAPH is about 175 hours (37°C at neutral pH), making the rate of free radical generation essentially constant during the first several hours in solution.{9745} While AAPH may be used effectively for lipid peroxidation in aqueous dispersions of fatty acids, other radical generators may be better suited for peroxidation studies in lipid micelles or membranes.{9746,8841}
Brand:CaymanSKU:82235 - 10 gAvailable on backorder
AAPH is a water-soluble azo compound which is used extensively as a free radical generator, often in the study of lipid peroxidation and the characterization of antioxidants.{6422,7745,9407,9459} Decomposition of AAPH produces molecular nitrogen and 2 carbon radicals. The carbon radicals may combine to produce stable products or react with molecular oxygen to give peroxyl radicals. The half-life of AAPH is about 175 hours (37°C at neutral pH), making the rate of free radical generation essentially constant during the first several hours in solution.{9745} While AAPH may be used effectively for lipid peroxidation in aqueous dispersions of fatty acids, other radical generators may be better suited for peroxidation studies in lipid micelles or membranes.{9746,8841}
Brand:CaymanSKU:82235 - 5 gAvailable on backorder
Aaptamine is a marine sponge alkaloid originally isolated from A. aaptos with diverse biological activities, including antiproliferative and antidepressant properties.{47125,47126,47127,47128} It is an agonist of δ- and μ-opioid receptors (EC50s = 5.1 and 10.1 μM, respectively, in HEK293 cells expressing human recombinant receptors) and a competitive antagonist of α-adrenergic receptors (α-ARs; pA2s = 4.88 and 5.43, respectively, in isolated rabbit aorta and renal artery).{47125,47128} Aaptamine inhibits growth of HeLa cervical cancer (IC50 = 15 μg/ml) and K562 leukemia (GI50 = 10 μM) cells and induces cell cycle arrest in the G2/M phase in K562 leukemia and MG63 osteosarcoma cells.{47126,47127,47129} It is a proteasome inhibitor that inhibits chymotrypsin-, caspase-, and trypsin-like activity in a partially purified rat liver proteasome preparation (IC50s = 1.6, 2.7, and 18 μg/ml, respectively) and dose-dependently activates p21 independent of p53 in MG63 cells when used at concentrations ranging from 20 to 50 μM.{47126,47129} Aaptamine (40 mg/kg, i.p.) decreases immobility time in the forced swim test in mice, indicating antidepressant-like activity.{47128}
Brand:CaymanSKU:24297 - 1 mgAvailable on backorder
Aaptamine is a marine sponge alkaloid originally isolated from A. aaptos with diverse biological activities, including antiproliferative and antidepressant properties.{47125,47126,47127,47128} It is an agonist of δ- and μ-opioid receptors (EC50s = 5.1 and 10.1 μM, respectively, in HEK293 cells expressing human recombinant receptors) and a competitive antagonist of α-adrenergic receptors (α-ARs; pA2s = 4.88 and 5.43, respectively, in isolated rabbit aorta and renal artery).{47125,47128} Aaptamine inhibits growth of HeLa cervical cancer (IC50 = 15 μg/ml) and K562 leukemia (GI50 = 10 μM) cells and induces cell cycle arrest in the G2/M phase in K562 leukemia and MG63 osteosarcoma cells.{47126,47127,47129} It is a proteasome inhibitor that inhibits chymotrypsin-, caspase-, and trypsin-like activity in a partially purified rat liver proteasome preparation (IC50s = 1.6, 2.7, and 18 μg/ml, respectively) and dose-dependently activates p21 independent of p53 in MG63 cells when used at concentrations ranging from 20 to 50 μM.{47126,47129} Aaptamine (40 mg/kg, i.p.) decreases immobility time in the forced swim test in mice, indicating antidepressant-like activity.{47128}
Brand:CaymanSKU:24297 - 500 µgAvailable on backorder
AAT-008 is an orally bioavailable and potent antagonist of the prostaglandin E2 (PGE2) receptor subtype 4 (EP4; IC50 = 16.3 nM in a human EP4 functional assay).{33448} It is selective for EP4 with IC50 values of 2.4, 1,890, >20,000, and >20,000 nM for binding to human recombinant EP4, EP2, EP1, and EP3, respectively. AAT-008 has potent binding affinity for human, rat, and dog EP4 (Kis = 0.97, 6.1, and 38 nM, respectively) and suppresses PGE2-induced elevation of intracellular cAMP with an antagonistic potency (pA2) of 1.1 nM in vitro. Oral administration of AAT-008 reduces carrageenan-induced mechanical hyperalgesia in rats in a dose-dependent manner.
Brand:CaymanSKU:21810 -Out of stock
AAT-008 is an orally bioavailable and potent antagonist of the prostaglandin E2 (PGE2) receptor subtype 4 (EP4; IC50 = 16.3 nM in a human EP4 functional assay).{33448} It is selective for EP4 with IC50 values of 2.4, 1,890, >20,000, and >20,000 nM for binding to human recombinant EP4, EP2, EP1, and EP3, respectively. AAT-008 has potent binding affinity for human, rat, and dog EP4 (Kis = 0.97, 6.1, and 38 nM, respectively) and suppresses PGE2-induced elevation of intracellular cAMP with an antagonistic potency (pA2) of 1.1 nM in vitro. Oral administration of AAT-008 reduces carrageenan-induced mechanical hyperalgesia in rats in a dose-dependent manner.
Brand:CaymanSKU:21810 -Out of stock
AAT-008 is an orally bioavailable and potent antagonist of the prostaglandin E2 (PGE2) receptor subtype 4 (EP4; IC50 = 16.3 nM in a human EP4 functional assay).{33448} It is selective for EP4 with IC50 values of 2.4, 1,890, >20,000, and >20,000 nM for binding to human recombinant EP4, EP2, EP1, and EP3, respectively. AAT-008 has potent binding affinity for human, rat, and dog EP4 (Kis = 0.97, 6.1, and 38 nM, respectively) and suppresses PGE2-induced elevation of intracellular cAMP with an antagonistic potency (pA2) of 1.1 nM in vitro. Oral administration of AAT-008 reduces carrageenan-induced mechanical hyperalgesia in rats in a dose-dependent manner.
Brand:CaymanSKU:21810 -Out of stock
AAT-008 is an orally bioavailable and potent antagonist of the prostaglandin E2 (PGE2) receptor subtype 4 (EP4; IC50 = 16.3 nM in a human EP4 functional assay).{33448} It is selective for EP4 with IC50 values of 2.4, 1,890, >20,000, and >20,000 nM for binding to human recombinant EP4, EP2, EP1, and EP3, respectively. AAT-008 has potent binding affinity for human, rat, and dog EP4 (Kis = 0.97, 6.1, and 38 nM, respectively) and suppresses PGE2-induced elevation of intracellular cAMP with an antagonistic potency (pA2) of 1.1 nM in vitro. Oral administration of AAT-008 reduces carrageenan-induced mechanical hyperalgesia in rats in a dose-dependent manner.
Brand:CaymanSKU:21810 -Out of stock
![A synthetic CB built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs; may have selectivity for the CB2 receptor; intended for forensic and research applications](https://interpriseusa.com/wp-content/uploads/2021/06/11766.png)
AB-005 is a synthetic cannabinoid (CB) built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs, including AM1220 (Item No. 9001055), AM1241 (Item No. 10010118), and AM1248 (Item No. 11282).{20430} The addition of a tetramethylcyclopropyl group has, in some cases, increased selectivity of synthetic CBs for the peripheral CB2 receptor.{21031} The physiological and toxicological properties of this compound have not been established. This product is intended for forensic and research applications.
Brand:CaymanSKU:11766 - 1 mgAvailable on backorder
AB-005 is a synthetic cannabinoid (CB) built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs, including AM1220 (Item No. 9001055), AM1241 (Item No. 10010118), and AM1248 (Item No. 11282).{20430} The addition of a tetramethylcyclopropyl group has, in some cases, increased selectivity of synthetic CBs for the peripheral CB2 receptor.{21031} The physiological and toxicological properties of this compound have not been established. This product is intended for forensic and research applications.
Brand:CaymanSKU:11766 - 10 mgAvailable on backorder
AB-005 is a synthetic cannabinoid (CB) built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs, including AM1220 (Item No. 9001055), AM1241 (Item No. 10010118), and AM1248 (Item No. 11282).{20430} The addition of a tetramethylcyclopropyl group has, in some cases, increased selectivity of synthetic CBs for the peripheral CB2 receptor.{21031} The physiological and toxicological properties of this compound have not been established. This product is intended for forensic and research applications.
Brand:CaymanSKU:11766 - 5 mgAvailable on backorder
AB-005 (Item No. 11766) is a synthetic cannabinoid (CB) built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs, including AM1220 (Item No. 9001055), AM1241 (Item No. 10010118), and AM1248 (Item No. 11282).{20430} AB-005 azepane isomer is a variant of AB-005 in which the methylpiperidine group has been replaced with methylazepane. The physiological and toxicological properties of this compound have not been established. This product is intended for forensic and research applications.
Brand:CaymanSKU:11877 - 1 mgAvailable on backorder
AB-005 (Item No. 11766) is a synthetic cannabinoid (CB) built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs, including AM1220 (Item No. 9001055), AM1241 (Item No. 10010118), and AM1248 (Item No. 11282).{20430} AB-005 azepane isomer is a variant of AB-005 in which the methylpiperidine group has been replaced with methylazepane. The physiological and toxicological properties of this compound have not been established. This product is intended for forensic and research applications.
Brand:CaymanSKU:11877 - 10 mgAvailable on backorder
AB-005 (Item No. 11766) is a synthetic cannabinoid (CB) built on a 1-[(1-methylpiperidin-2-yl)methyl]-indole base that is characteristic of a series of potent CBs, including AM1220 (Item No. 9001055), AM1241 (Item No. 10010118), and AM1248 (Item No. 11282).{20430} AB-005 azepane isomer is a variant of AB-005 in which the methylpiperidine group has been replaced with methylazepane. The physiological and toxicological properties of this compound have not been established. This product is intended for forensic and research applications.
Brand:CaymanSKU:11877 - 5 mgAvailable on backorder
AB-928 is an adenosine A2A and A2B receptor dual antagonist.{58116} It inhibits the ability of adenosine (Item No. 21232) to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, in vitro.{58117,58118} AB-928, alone or in combination with doxorubicin (Item No. 15007), reduces tumor growth in an AT3-OVA syngeneic mouse model. It also acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model.
Brand:CaymanSKU:31444 - 10 mgAvailable on backorder
AB-928 is an adenosine A2A and A2B receptor dual antagonist.{58116} It inhibits the ability of adenosine (Item No. 21232) to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, in vitro.{58117,58118} AB-928, alone or in combination with doxorubicin (Item No. 15007), reduces tumor growth in an AT3-OVA syngeneic mouse model. It also acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model.
Brand:CaymanSKU:31444 - 25 mgAvailable on backorder
AB-928 is an adenosine A2A and A2B receptor dual antagonist.{58116} It inhibits the ability of adenosine (Item No. 21232) to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, in vitro.{58117,58118} AB-928, alone or in combination with doxorubicin (Item No. 15007), reduces tumor growth in an AT3-OVA syngeneic mouse model. It also acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model.
Brand:CaymanSKU:31444 - 5 mgAvailable on backorder
AB-928 is an adenosine A2A and A2B receptor dual antagonist.{58116} It inhibits the ability of adenosine (Item No. 21232) to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, in vitro.{58117,58118} AB-928, alone or in combination with doxorubicin (Item No. 15007), reduces tumor growth in an AT3-OVA syngeneic mouse model. It also acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model.
Brand:CaymanSKU:31444 - 50 mgAvailable on backorder
AB-BICA (Item No. 18759) is an analytical reference standard that is structurally classified as a synthetic cannabinoid.{31681} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications
Brand:CaymanSKU:-Available on backorder
AB-BICA (Item No. 18759) is an analytical reference standard that is structurally classified as a synthetic cannabinoid.{31681} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications
Brand:CaymanSKU:-Available on backorder
AB-CHMINACA (Item No. 15434) is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA (Item No. 14039), a high affinity ligand of the central CB1 receptor (Ki = 0.9 nM).{22006,22072} AB-CHMINACA metabolite M2 is a metabolite of AB-CHMINACA that can be detected in the urine.{29562} The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Brand:CaymanSKU:-Out of stock
AB-CHMINACA (Item No. 15434) is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA (Item No. 14039), a high affinity ligand of the central CB1 receptor (Ki = 0.9 nM).{22006,22072} AB-CHMINACA metabolite M2 is a metabolite of AB-CHMINACA that can be detected in the urine.{29562} The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Brand:CaymanSKU:-Out of stock
AB-CHMINACA (Item No. 15434) is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA (Item No. 14039), a high affinity ligand of the central CB1 receptor (Ki = 0.9 nM).{22006,22072} AB-CHMINACA metabolite M2 is a metabolite of AB-CHMINACA that can be detected in the urine.{29562} The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Brand:CaymanSKU:-Out of stock
AB-CHMINACA metabolite M4 RM (Item No. 16393) is an analytical reference standard that is structurally categorized as a synthetic cannabinoid. It is an expected metabolite of AB-CHMINACA (Item No. 15434) in which the carboxamide-linked aminocarbonyl-2-methylpropyl side chain associated with both AB-CHMINACA and AB-FUBINACA has been replaced with a carboxyl group. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:-Out of stock
AB-CHMINACA metabolite M4 RM (Item No. 16393) is an analytical reference standard that is structurally categorized as a synthetic cannabinoid. It is an expected metabolite of AB-CHMINACA (Item No. 15434) in which the carboxamide-linked aminocarbonyl-2-methylpropyl side chain associated with both AB-CHMINACA and AB-FUBINACA has been replaced with a carboxyl group. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:-Out of stock
AB-CHMINACA metabolite M4 RM (Item No. 16393) is an analytical reference standard that is structurally categorized as a synthetic cannabinoid. It is an expected metabolite of AB-CHMINACA (Item No. 15434) in which the carboxamide-linked aminocarbonyl-2-methylpropyl side chain associated with both AB-CHMINACA and AB-FUBINACA has been replaced with a carboxyl group. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:-Out of stock
AB-FUBINACA (Item No. 14039) is an indazole-based synthetic cannabinoid (CB) that potently binds the central CB1 receptor (Ki = 0.9 nM).{22006,22072} This compound has been identified along with AB-PINACA (Item No. 14038) in illegal herbal products.{22006,22072} AB-FUBINACA 3-fluorobenzyl isomer is an isomer of AB-FUBINACA that differs by having the fluoro group at the three, rather than four, position on the benzyl group. This compound binds CB1 with a Ki value of 51.1 nM.{22072} This product is intended for research and forensic applications.
Brand:CaymanSKU:9001523 - 1 mgAvailable on backorder
AB-FUBINACA (Item No. 14039) is an indazole-based synthetic cannabinoid (CB) that potently binds the central CB1 receptor (Ki = 0.9 nM).{22006,22072} This compound has been identified along with AB-PINACA (Item No. 14038) in illegal herbal products.{22006,22072} AB-FUBINACA 3-fluorobenzyl isomer is an isomer of AB-FUBINACA that differs by having the fluoro group at the three, rather than four, position on the benzyl group. This compound binds CB1 with a Ki value of 51.1 nM.{22072} This product is intended for research and forensic applications.
Brand:CaymanSKU:9001523 - 10 mgAvailable on backorder
AB-FUBINACA (Item No. 14039) is an indazole-based synthetic cannabinoid (CB) that potently binds the central CB1 receptor (Ki = 0.9 nM).{22006,22072} This compound has been identified along with AB-PINACA (Item No. 14038) in illegal herbal products.{22006,22072} AB-FUBINACA 3-fluorobenzyl isomer is an isomer of AB-FUBINACA that differs by having the fluoro group at the three, rather than four, position on the benzyl group. This compound binds CB1 with a Ki value of 51.1 nM.{22072} This product is intended for research and forensic applications.
Brand:CaymanSKU:9001523 - 5 mgAvailable on backorder
AB-FUBINACA (Item No. 14039) is an adamantylindole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 (Item No. 10900).{22006,22072} AB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.{22006,22072} AB-FUBINACA isomer 2 is a regioisomer of AB-FUBINACA. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:9001529 - 1 mgAvailable on backorder
AB-FUBINACA (Item No. 14039) is an adamantylindole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 (Item No. 10900).{22006,22072} AB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.{22006,22072} AB-FUBINACA isomer 2 is a regioisomer of AB-FUBINACA. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:9001529 - 10 mgAvailable on backorder
AB-FUBINACA (Item No. 14039) is an adamantylindole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 (Item No. 10900).{22006,22072} AB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.{22006,22072} AB-FUBINACA isomer 2 is a regioisomer of AB-FUBINACA. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:9001529 - 5 mgAvailable on backorder
AB-FUBINACA metabolite 4 (Item No. 20179) is an analytical reference standard that is structurally classified as a synthetic cannabinoid. It is the carboxylic acid indazole 4-fluorobenzyl metabolite of AB-FUBINACA (Item Nos. 14039 | ISO60211).{30114} The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Brand:CaymanSKU:20179 -Available on backorder
AB-FUBINACA metabolite 4 (Item No. 20179) is an analytical reference standard that is structurally classified as a synthetic cannabinoid. It is the carboxylic acid indazole 4-fluorobenzyl metabolite of AB-FUBINACA (Item Nos. 14039 | ISO60211).{30114} The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Brand:CaymanSKU:20179 -Available on backorder
AB-MECA is an adenosine A3 receptor agonist (Ki = 430.5 nM for the human receptor expressed in CHO cells).{45426} It inhibits LPS-induced TNF-α production in primary cultured human lung macrophages (pD2 = 6.9).{45427} AB-MECA increases contraction of isolated guinea pig trachea ex vivo when used at a concentration of 0.1 μM and increases bronchoconstriction in vivo when administered at a dose of 3 μg/kg in a guinea pig model of ovalbumin-sensitized asthma.{45428} A radiolabeled form of AB-MECA has been used for radioligand binding assays and binds to rat adenosine A1 and A3 receptors (Kds = 3.42 and 1.48 nM in COS-7 and CHO cells, respectively) and canine adenosine A2a receptors (Kd = 25.1 nM in COS-7 cells).{45429}
Brand:CaymanSKU:28415 - 1 mgAvailable on backorder
AB-MECA is an adenosine A3 receptor agonist (Ki = 430.5 nM for the human receptor expressed in CHO cells).{45426} It inhibits LPS-induced TNF-α production in primary cultured human lung macrophages (pD2 = 6.9).{45427} AB-MECA increases contraction of isolated guinea pig trachea ex vivo when used at a concentration of 0.1 μM and increases bronchoconstriction in vivo when administered at a dose of 3 μg/kg in a guinea pig model of ovalbumin-sensitized asthma.{45428} A radiolabeled form of AB-MECA has been used for radioligand binding assays and binds to rat adenosine A1 and A3 receptors (Kds = 3.42 and 1.48 nM in COS-7 and CHO cells, respectively) and canine adenosine A2a receptors (Kd = 25.1 nM in COS-7 cells).{45429}
Brand:CaymanSKU:28415 - 10 mgAvailable on backorder
AB-MECA is an adenosine A3 receptor agonist (Ki = 430.5 nM for the human receptor expressed in CHO cells).{45426} It inhibits LPS-induced TNF-α production in primary cultured human lung macrophages (pD2 = 6.9).{45427} AB-MECA increases contraction of isolated guinea pig trachea ex vivo when used at a concentration of 0.1 μM and increases bronchoconstriction in vivo when administered at a dose of 3 μg/kg in a guinea pig model of ovalbumin-sensitized asthma.{45428} A radiolabeled form of AB-MECA has been used for radioligand binding assays and binds to rat adenosine A1 and A3 receptors (Kds = 3.42 and 1.48 nM in COS-7 and CHO cells, respectively) and canine adenosine A2a receptors (Kd = 25.1 nM in COS-7 cells).{45429}
Brand:CaymanSKU:28415 - 5 mgAvailable on backorder
AB-PINACA 3-carboxyindazole metabolite (Item No. 27732) is an analytical reference standard that is structurally similar to known synthetic cannabinoid metabolites. This product is intended for research and forensic applications.
Brand:CaymanSKU:27732 - 1 mgAvailable on backorder
AB-PINACA 3-carboxyindazole metabolite (Item No. 27732) is an analytical reference standard that is structurally similar to known synthetic cannabinoid metabolites. This product is intended for research and forensic applications.
Brand:CaymanSKU:27732 - 5 mgAvailable on backorder
AB-PINACA (Item No. 14038) is a synthetic cannabinoid (CB) that has been identified in illegal herbal products.{22006} AB-PINACA pentanoic acid metabolite is an expected compound produced by phase I metabolism of AB-PINACA in vivo, based on the metabolism of comparable alkylindole CBs.{18291,20170} The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:- AB-PINACA (Item No. 14038) is a synthetic cannabinoid (CB) that has been identified in illegal herbal products.{22006} AB-PINACA pentanoic acid metabolite is an expected compound produced by phase I metabolism of AB-PINACA in vivo, based on the metabolism of comparable alkylindole CBs.{18291,20170} The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:- AB-PINACA (Item No. 14038) is a synthetic cannabinoid (CB) that has been identified in illegal herbal products.{22006} AB-PINACA pentanoic acid metabolite is an expected compound produced by phase I metabolism of AB-PINACA in vivo, based on the metabolism of comparable alkylindole CBs.{18291,20170} The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.
Brand:CaymanSKU:-
Abacavir is a nucleoside analog and an inhibitor of HIV-1 reverse transcriptase (Ki = 2.1 µM for the wild-type enzyme).{18404} It inhibits replication of a variety of HIV-1 and HIV-2 strains, including strains resistant to 3′-azido-3′-deoxythymidine (zidovudine; Item No. 15492) or 2′,3′-dideoxyinosine (didanosine; Item No. 23715), in HeLa cells stably expressing CD4 (IC50s = 5.8-21 µM). Abacavir inhibits replication of eight HIV-1 clinical isolates in phytohemagglutinin-stimulated isolated human peripheral blood lymphocytes with a mean IC50 value of 0.26 µM. It inhibits hepatitis B virus (HBV) DNA synthesis in HepG2 cells (IC50 = 7 µM) and is also active against human cytomegalovirus (CMV) strain AD169 and the Petaluma strain of feline immunodeficiency virus (FIV) in plaque reduction assays (IC50s = 32 and 0.4 µM, respectively). Formulations containing abacavir have been used in the treatment of HIV infection.
Brand:CaymanSKU:- Abacavir is a nucleoside analog and an inhibitor of HIV-1 reverse transcriptase (Ki = 2.1 µM for the wild-type enzyme).{18404} It inhibits replication of a variety of HIV-1 and HIV-2 strains, including strains resistant to 3′-azido-3′-deoxythymidine (zidovudine; Item No. 15492) or 2′,3′-dideoxyinosine (didanosine; Item No. 23715), in HeLa cells stably expressing CD4 (IC50s = 5.8-21 µM). Abacavir inhibits replication of eight HIV-1 clinical isolates in phytohemagglutinin-stimulated isolated human peripheral blood lymphocytes with a mean IC50 value of 0.26 µM. It inhibits hepatitis B virus (HBV) DNA synthesis in HepG2 cells (IC50 = 7 µM) and is also active against human cytomegalovirus (CMV) strain AD169 and the Petaluma strain of feline immunodeficiency virus (FIV) in plaque reduction assays (IC50s = 32 and 0.4 µM, respectively). Formulations containing abacavir have been used in the treatment of HIV infection.
Brand:CaymanSKU:- Abacavir is a nucleoside analog and an inhibitor of HIV-1 reverse transcriptase (Ki = 2.1 µM for the wild-type enzyme).{18404} It inhibits replication of a variety of HIV-1 and HIV-2 strains, including strains resistant to 3′-azido-3′-deoxythymidine (zidovudine; Item No. 15492) or 2′,3′-dideoxyinosine (didanosine; Item No. 23715), in HeLa cells stably expressing CD4 (IC50s = 5.8-21 µM). Abacavir inhibits replication of eight HIV-1 clinical isolates in phytohemagglutinin-stimulated isolated human peripheral blood lymphocytes with a mean IC50 value of 0.26 µM. It inhibits hepatitis B virus (HBV) DNA synthesis in HepG2 cells (IC50 = 7 µM) and is also active against human cytomegalovirus (CMV) strain AD169 and the Petaluma strain of feline immunodeficiency virus (FIV) in plaque reduction assays (IC50s = 32 and 0.4 µM, respectively). Formulations containing abacavir have been used in the treatment of HIV infection.
Brand:CaymanSKU:- Abacavir is a nucleoside analog and an inhibitor of HIV-1 reverse transcriptase (Ki = 2.1 µM for the wild-type enzyme).{18404} It inhibits replication of a variety of HIV-1 and HIV-2 strains, including strains resistant to 3′-azido-3′-deoxythymidine (zidovudine; Item No. 15492) or 2′,3′-dideoxyinosine (didanosine; Item No. 23715), in HeLa cells stably expressing CD4 (IC50s = 5.8-21 µM). Abacavir inhibits replication of eight HIV-1 clinical isolates in phytohemagglutinin-stimulated isolated human peripheral blood lymphocytes with a mean IC50 value of 0.26 µM. It inhibits hepatitis B virus (HBV) DNA synthesis in HepG2 cells (IC50 = 7 µM) and is also active against human cytomegalovirus (CMV) strain AD169 and the Petaluma strain of feline immunodeficiency virus (FIV) in plaque reduction assays (IC50s = 32 and 0.4 µM, respectively). Formulations containing abacavir have been used in the treatment of HIV infection.
Brand:CaymanSKU:-
Abacavir carboxylate is an inactive metabolite of the HIV-1 reverse transcriptase inhibitor abacavir (Item No. 14746).{43845,43846} It is formed from abacavir via reactive aldehyde intermediates that can form adducts with proteins on valine residues.{43846}
Brand:CaymanSKU:27777 - 1 mgAvailable on backorder
Abacavir-d4 is intended for use as an internal standard for the quantification of abacavir (Item No. 14746) by GC- or LC-MS. Abacavir is a nucleoside analog and an inhibitor of HIV-1 reverse transcriptase (Ki = 2.1 µM for the wild-type enzyme).{18404} It inhibits replication of a variety of HIV-1 and HIV-2 strains, including strains resistant to 3′-azido-3′-deoxythymidine (zidovudine; Item No. 15492) or 2′,3′-dideoxyinosine (didanosine; Item No. 23715), in HeLa cells stably expressing CD4 (IC50s = 5.8-21 µM). Abacavir inhibits replication of eight HIV-1 clinical isolates in phytohemagglutinin-stimulated isolated human peripheral blood lymphocytes with a mean IC50 value of 0.26 µM. It inhibits hepatitis B virus (HBV) DNA synthesis in HepG2 cells (IC50 = 7 µM) and is also active against human cytomegalovirus (CMV) strain AD169 and the Petaluma strain of feline immunodeficiency virus (FIV) in plaque reduction assays (IC50s = 32 and 0.4 µM, respectively). Formulations containing abacavir have been used in the treatment of HIV infection.
Brand:CaymanSKU:30076 - 1 mgAvailable on backorder
Abacavir-d4 is intended for use as an internal standard for the quantification of abacavir (Item No. 14746) by GC- or LC-MS. Abacavir is a nucleoside analog and an inhibitor of HIV-1 reverse transcriptase (Ki = 2.1 µM for the wild-type enzyme).{18404} It inhibits replication of a variety of HIV-1 and HIV-2 strains, including strains resistant to 3′-azido-3′-deoxythymidine (zidovudine; Item No. 15492) or 2′,3′-dideoxyinosine (didanosine; Item No. 23715), in HeLa cells stably expressing CD4 (IC50s = 5.8-21 µM). Abacavir inhibits replication of eight HIV-1 clinical isolates in phytohemagglutinin-stimulated isolated human peripheral blood lymphocytes with a mean IC50 value of 0.26 µM. It inhibits hepatitis B virus (HBV) DNA synthesis in HepG2 cells (IC50 = 7 µM) and is also active against human cytomegalovirus (CMV) strain AD169 and the Petaluma strain of feline immunodeficiency virus (FIV) in plaque reduction assays (IC50s = 32 and 0.4 µM, respectively). Formulations containing abacavir have been used in the treatment of HIV infection.
Brand:CaymanSKU:30076 - 500 µgAvailable on backorder
Abamectin is a mixture of the natural macrocyclic lactones avermectin B1a and avermectin B1b (Item No. 17453). It has both insecticidal and anthelmintic actions and is used in both agriculture and veterinary medicine.{31111,31112,31113,31114} Abamectin can inhibit nicotinic acetylcholine receptors of worms.{31083} It can also inhibit chikungunya virus (EC50 = 1.5 µM) and yellow fever virus.{31115}
Brand:CaymanSKU:-Available on backorder
Abamectin is a mixture of the natural macrocyclic lactones avermectin B1a and avermectin B1b (Item No. 17453). It has both insecticidal and anthelmintic actions and is used in both agriculture and veterinary medicine.{31111,31112,31113,31114} Abamectin can inhibit nicotinic acetylcholine receptors of worms.{31083} It can also inhibit chikungunya virus (EC50 = 1.5 µM) and yellow fever virus.{31115}
Brand:CaymanSKU:-Available on backorder
Abametapir is a building block and an insectide.{57166,57167,57168} It has been used in the synthesis of lanthanide coordination complexes with antifungal activity against C. albicans and divalent vancomycin derivatives with antibacterial activity against vancomycin-resistant enterococci.{57166,57167} Abametapir is ovicidal to DDT- and permethrin-resistant head louse eggs (LC50s = 0.108, 0.121, and 0.16% in isopropanol for 0-2-, 3-5-, and 6-8-day-old eggs, respectively).{57168} Formulations containing abametapir have been used in the topical treatment of head lice infestation.
Brand:CaymanSKU:30684 - 100 mgAvailable on backorder
Abametapir is a building block and an insectide.{57166,57167,57168} It has been used in the synthesis of lanthanide coordination complexes with antifungal activity against C. albicans and divalent vancomycin derivatives with antibacterial activity against vancomycin-resistant enterococci.{57166,57167} Abametapir is ovicidal to DDT- and permethrin-resistant head louse eggs (LC50s = 0.108, 0.121, and 0.16% in isopropanol for 0-2-, 3-5-, and 6-8-day-old eggs, respectively).{57168} Formulations containing abametapir have been used in the topical treatment of head lice infestation.
Brand:CaymanSKU:30684 - 50 mgAvailable on backorder
Abarelix is a synthetic third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist (IC50 = 3.5 nM in HEK293 cells expressing the human receptor).{48583,39553} In vivo, abarelix (200 μg/kg) decreases plasma luteinizing hormone (LH) levels six hours post-treatment in castrated rats, with levels returning to baseline within 24 hours.{48584} Abarelix (2 mg/kg) also transiently decreases plasma testosterone levels in intact rats, with levels returning to baseline within seven days post-treatment. Formulations containing abarelix have previously been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:28746 - 1 mgAvailable on backorder
Abarelix is a synthetic third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist (IC50 = 3.5 nM in HEK293 cells expressing the human receptor).{48583,39553} In vivo, abarelix (200 μg/kg) decreases plasma luteinizing hormone (LH) levels six hours post-treatment in castrated rats, with levels returning to baseline within 24 hours.{48584} Abarelix (2 mg/kg) also transiently decreases plasma testosterone levels in intact rats, with levels returning to baseline within seven days post-treatment. Formulations containing abarelix have previously been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:28746 - 10 mgAvailable on backorder
Abarelix is a synthetic third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist (IC50 = 3.5 nM in HEK293 cells expressing the human receptor).{48583,39553} In vivo, abarelix (200 μg/kg) decreases plasma luteinizing hormone (LH) levels six hours post-treatment in castrated rats, with levels returning to baseline within 24 hours.{48584} Abarelix (2 mg/kg) also transiently decreases plasma testosterone levels in intact rats, with levels returning to baseline within seven days post-treatment. Formulations containing abarelix have previously been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:28746 - 25 mgAvailable on backorder
Abarelix is a synthetic third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist (IC50 = 3.5 nM in HEK293 cells expressing the human receptor).{48583,39553} In vivo, abarelix (200 μg/kg) decreases plasma luteinizing hormone (LH) levels six hours post-treatment in castrated rats, with levels returning to baseline within 24 hours.{48584} Abarelix (2 mg/kg) also transiently decreases plasma testosterone levels in intact rats, with levels returning to baseline within seven days post-treatment. Formulations containing abarelix have previously been used in the treatment of advanced prostate cancer.
Brand:CaymanSKU:28746 - 5 mgAvailable on backorder
ABBV-075 is a potent inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that is selective for the bromodomain-containing proteins (BRD) BRD2, BRD4, and BRDT (Kis = 1-2.2 nM) over BRD3 (Ki = 12.2 nM) and against a panel of 18 BRD proteins.{34796} It inhibits BRD4 recruitment to androgen receptor-occupied gene enhancer sites leading to growth inhibition in androgen receptor-dependent prostate cancer cells.{34795} ABBV-075 halts the cell cycle in the G1 phase and induces apoptosis in prostate cancer cells as well as patient-derived acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.{34794} It is also efficacious in many xenograft mouse models including lung and prostate cancers, AML, and multiple myeloma.{34796,34795,34794} Formulations containing ABBV-075 are in clinical trials for the treatment of advanced hematologic malignancies and solid tumors.
Brand:CaymanSKU:21033 -Out of stock
ABBV-075 is a potent inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that is selective for the bromodomain-containing proteins (BRD) BRD2, BRD4, and BRDT (Kis = 1-2.2 nM) over BRD3 (Ki = 12.2 nM) and against a panel of 18 BRD proteins.{34796} It inhibits BRD4 recruitment to androgen receptor-occupied gene enhancer sites leading to growth inhibition in androgen receptor-dependent prostate cancer cells.{34795} ABBV-075 halts the cell cycle in the G1 phase and induces apoptosis in prostate cancer cells as well as patient-derived acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.{34794} It is also efficacious in many xenograft mouse models including lung and prostate cancers, AML, and multiple myeloma.{34796,34795,34794} Formulations containing ABBV-075 are in clinical trials for the treatment of advanced hematologic malignancies and solid tumors.
Brand:CaymanSKU:21033 -Out of stock
ABBV-075 is a potent inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that is selective for the bromodomain-containing proteins (BRD) BRD2, BRD4, and BRDT (Kis = 1-2.2 nM) over BRD3 (Ki = 12.2 nM) and against a panel of 18 BRD proteins.{34796} It inhibits BRD4 recruitment to androgen receptor-occupied gene enhancer sites leading to growth inhibition in androgen receptor-dependent prostate cancer cells.{34795} ABBV-075 halts the cell cycle in the G1 phase and induces apoptosis in prostate cancer cells as well as patient-derived acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.{34794} It is also efficacious in many xenograft mouse models including lung and prostate cancers, AML, and multiple myeloma.{34796,34795,34794} Formulations containing ABBV-075 are in clinical trials for the treatment of advanced hematologic malignancies and solid tumors.
Brand:CaymanSKU:21033 -Out of stock
ABBV-075 is a potent inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that is selective for the bromodomain-containing proteins (BRD) BRD2, BRD4, and BRDT (Kis = 1-2.2 nM) over BRD3 (Ki = 12.2 nM) and against a panel of 18 BRD proteins.{34796} It inhibits BRD4 recruitment to androgen receptor-occupied gene enhancer sites leading to growth inhibition in androgen receptor-dependent prostate cancer cells.{34795} ABBV-075 halts the cell cycle in the G1 phase and induces apoptosis in prostate cancer cells as well as patient-derived acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.{34794} It is also efficacious in many xenograft mouse models including lung and prostate cancers, AML, and multiple myeloma.{34796,34795,34794} Formulations containing ABBV-075 are in clinical trials for the treatment of advanced hematologic malignancies and solid tumors.
Brand:CaymanSKU:21033 -Out of stock
ABBV-744 is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2; Kis = 4.6, 4.9, 1.6, and 1 nM for BRD2, -3, -4, and -T, respectively).{58046} It is selective for BD2 over BD1 bromodomains in a time-resolved FRET (TR-FRET) assay (Kis = 1,162, 3,140, 521, and 917 nM for BRD2, -3, -4, and -T, respectively). ABBV-744 inhibits proliferation of SKM-1 leukemia cells (IC50 = 6.7 nM). It induces cell cycle arrest at the G1 phase in LNCaP prostate cancer cells.{58047} ABBV-744 (18.8 mg/kg) reduces tumor volume in a SKM-1 mouse xenograft model.{58046} It also reduces tumor growth in LNCaP and MDA PCa 2b mouse xenograft models when administered at doses of 1 and 4.7 mg/kg.{58047}
Brand:CaymanSKU:30470 - 10 mgAvailable on backorder
ABBV-744 is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2; Kis = 4.6, 4.9, 1.6, and 1 nM for BRD2, -3, -4, and -T, respectively).{58046} It is selective for BD2 over BD1 bromodomains in a time-resolved FRET (TR-FRET) assay (Kis = 1,162, 3,140, 521, and 917 nM for BRD2, -3, -4, and -T, respectively). ABBV-744 inhibits proliferation of SKM-1 leukemia cells (IC50 = 6.7 nM). It induces cell cycle arrest at the G1 phase in LNCaP prostate cancer cells.{58047} ABBV-744 (18.8 mg/kg) reduces tumor volume in a SKM-1 mouse xenograft model.{58046} It also reduces tumor growth in LNCaP and MDA PCa 2b mouse xenograft models when administered at doses of 1 and 4.7 mg/kg.{58047}
Brand:CaymanSKU:30470 - 25 mgAvailable on backorder
ABBV-744 is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2; Kis = 4.6, 4.9, 1.6, and 1 nM for BRD2, -3, -4, and -T, respectively).{58046} It is selective for BD2 over BD1 bromodomains in a time-resolved FRET (TR-FRET) assay (Kis = 1,162, 3,140, 521, and 917 nM for BRD2, -3, -4, and -T, respectively). ABBV-744 inhibits proliferation of SKM-1 leukemia cells (IC50 = 6.7 nM). It induces cell cycle arrest at the G1 phase in LNCaP prostate cancer cells.{58047} ABBV-744 (18.8 mg/kg) reduces tumor volume in a SKM-1 mouse xenograft model.{58046} It also reduces tumor growth in LNCaP and MDA PCa 2b mouse xenograft models when administered at doses of 1 and 4.7 mg/kg.{58047}
Brand:CaymanSKU:30470 - 5 mgAvailable on backorder
ABBV-744 is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2; Kis = 4.6, 4.9, 1.6, and 1 nM for BRD2, -3, -4, and -T, respectively).{58046} It is selective for BD2 over BD1 bromodomains in a time-resolved FRET (TR-FRET) assay (Kis = 1,162, 3,140, 521, and 917 nM for BRD2, -3, -4, and -T, respectively). ABBV-744 inhibits proliferation of SKM-1 leukemia cells (IC50 = 6.7 nM). It induces cell cycle arrest at the G1 phase in LNCaP prostate cancer cells.{58047} ABBV-744 (18.8 mg/kg) reduces tumor volume in a SKM-1 mouse xenograft model.{58046} It also reduces tumor growth in LNCaP and MDA PCa 2b mouse xenograft models when administered at doses of 1 and 4.7 mg/kg.{58047}
Brand:CaymanSKU:30470 - 50 mgAvailable on backorder
ABC294640 is an inhibitor of sphingosine kinase 2 (SPHK2; Ki = 9.8 μM).{18506} It inhibits SPHK2 (IC50 = 60 μM) without affecting SPHK1 activity up to 100 μM but does reduce SPHK1 isoform a (SPHK1a) protein levels in androgen-independent LNCaP (LNCaP-AI) cells via an SPHK1-indirect, proteasomal-dependent mechanism when used at concentrations ranging from 5 to 25 µM.{56206} ABC294640 is inactive against a panel of 20 lipid-regulated kinases at 50 μM.{18506} It decreases sphingosine-1-phosphate (S1P) production in MDA-MB-231 cells in a concentration-dependent manner. ABC294640 inhibits proliferation of a variety of cancer cells, including HepG2 liver, A-498 kidney, PANC-1 pancreas, and HT-29 colon cells (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively). It reduces actin filament polymerization in, and cell migration of, A-498 cells in a scratch assay. Oral administration of ABC294640 (35 and 100 mg/kg every other day) reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma. It also reduces colonic inflammation in mouse and rat models of Crohn’s disease induced by trinitrobenzene sulfonic acid (TNBS).{37136}
Brand:CaymanSKU:10587 - 1 mgAvailable on backorder
ABC294640 is an inhibitor of sphingosine kinase 2 (SPHK2; Ki = 9.8 μM).{18506} It inhibits SPHK2 (IC50 = 60 μM) without affecting SPHK1 activity up to 100 μM but does reduce SPHK1 isoform a (SPHK1a) protein levels in androgen-independent LNCaP (LNCaP-AI) cells via an SPHK1-indirect, proteasomal-dependent mechanism when used at concentrations ranging from 5 to 25 µM.{56206} ABC294640 is inactive against a panel of 20 lipid-regulated kinases at 50 μM.{18506} It decreases sphingosine-1-phosphate (S1P) production in MDA-MB-231 cells in a concentration-dependent manner. ABC294640 inhibits proliferation of a variety of cancer cells, including HepG2 liver, A-498 kidney, PANC-1 pancreas, and HT-29 colon cells (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively). It reduces actin filament polymerization in, and cell migration of, A-498 cells in a scratch assay. Oral administration of ABC294640 (35 and 100 mg/kg every other day) reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma. It also reduces colonic inflammation in mouse and rat models of Crohn’s disease induced by trinitrobenzene sulfonic acid (TNBS).{37136}
Brand:CaymanSKU:10587 - 10 mgAvailable on backorder
ABC294640 is an inhibitor of sphingosine kinase 2 (SPHK2; Ki = 9.8 μM).{18506} It inhibits SPHK2 (IC50 = 60 μM) without affecting SPHK1 activity up to 100 μM but does reduce SPHK1 isoform a (SPHK1a) protein levels in androgen-independent LNCaP (LNCaP-AI) cells via an SPHK1-indirect, proteasomal-dependent mechanism when used at concentrations ranging from 5 to 25 µM.{56206} ABC294640 is inactive against a panel of 20 lipid-regulated kinases at 50 μM.{18506} It decreases sphingosine-1-phosphate (S1P) production in MDA-MB-231 cells in a concentration-dependent manner. ABC294640 inhibits proliferation of a variety of cancer cells, including HepG2 liver, A-498 kidney, PANC-1 pancreas, and HT-29 colon cells (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively). It reduces actin filament polymerization in, and cell migration of, A-498 cells in a scratch assay. Oral administration of ABC294640 (35 and 100 mg/kg every other day) reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma. It also reduces colonic inflammation in mouse and rat models of Crohn’s disease induced by trinitrobenzene sulfonic acid (TNBS).{37136}
Brand:CaymanSKU:10587 - 25 mgAvailable on backorder
ABC294640 is an inhibitor of sphingosine kinase 2 (SPHK2; Ki = 9.8 μM).{18506} It inhibits SPHK2 (IC50 = 60 μM) without affecting SPHK1 activity up to 100 μM but does reduce SPHK1 isoform a (SPHK1a) protein levels in androgen-independent LNCaP (LNCaP-AI) cells via an SPHK1-indirect, proteasomal-dependent mechanism when used at concentrations ranging from 5 to 25 µM.{56206} ABC294640 is inactive against a panel of 20 lipid-regulated kinases at 50 μM.{18506} It decreases sphingosine-1-phosphate (S1P) production in MDA-MB-231 cells in a concentration-dependent manner. ABC294640 inhibits proliferation of a variety of cancer cells, including HepG2 liver, A-498 kidney, PANC-1 pancreas, and HT-29 colon cells (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively). It reduces actin filament polymerization in, and cell migration of, A-498 cells in a scratch assay. Oral administration of ABC294640 (35 and 100 mg/kg every other day) reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma. It also reduces colonic inflammation in mouse and rat models of Crohn’s disease induced by trinitrobenzene sulfonic acid (TNBS).{37136}
Brand:CaymanSKU:10587 - 5 mgAvailable on backorder
ABC34 is an inactive control probe for JJH260 (Item No. 19384), the inhibitor of androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs).{30849} ABC34 demonstrates an IC50 value greater than 25 µM for the inhibition of 9-PAHSA (Item No. 17037) but is more potent in blocking the serine hydrolase ABHD6 and the palmitoyl-protein hydrolase PPT1, which are both off-targets of JJH260.{30849}
Brand:CaymanSKU:-Available on backorder
ABC34 is an inactive control probe for JJH260 (Item No. 19384), the inhibitor of androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs).{30849} ABC34 demonstrates an IC50 value greater than 25 µM for the inhibition of 9-PAHSA (Item No. 17037) but is more potent in blocking the serine hydrolase ABHD6 and the palmitoyl-protein hydrolase PPT1, which are both off-targets of JJH260.{30849}
Brand:CaymanSKU:-Available on backorder
ABC34 is an inactive control probe for JJH260 (Item No. 19384), the inhibitor of androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs).{30849} ABC34 demonstrates an IC50 value greater than 25 µM for the inhibition of 9-PAHSA (Item No. 17037) but is more potent in blocking the serine hydrolase ABHD6 and the palmitoyl-protein hydrolase PPT1, which are both off-targets of JJH260.{30849}
Brand:CaymanSKU:-Available on backorder
ABC99 is an N-hydroxyhydantoin (NHH) carbamate that inhibits the Wnt-deacylating enzyme NOTUM (IC50 = 13 nM).{35387} It preserves Wnt3A signaling in the presence of NOTUM (EC50 = 89 nM in a cell-based reporter assay).
Brand:CaymanSKU:25858 - 1 mgAvailable on backorder
ABC99 is an N-hydroxyhydantoin (NHH) carbamate that inhibits the Wnt-deacylating enzyme NOTUM (IC50 = 13 nM).{35387} It preserves Wnt3A signaling in the presence of NOTUM (EC50 = 89 nM in a cell-based reporter assay).
Brand:CaymanSKU:25858 - 5 mgAvailable on backorder
ABC99 is an N-hydroxyhydantoin (NHH) carbamate that inhibits the Wnt-deacylating enzyme NOTUM (IC50 = 13 nM).{35387} It preserves Wnt3A signaling in the presence of NOTUM (EC50 = 89 nM in a cell-based reporter assay).
Brand:CaymanSKU:25858 - 500 µgAvailable on backorder
ABD459 is a neutral antagonist of the central cannabinoid 1 (CB1) receptor (Ki = 8.6 nM).{32470} It inhibits food consumption in nonfasted mice without affecting motor activity.{32470} ABD459 reduces active food seeking for 5-6 hours after treatment, with no rebound after washout. ABD459 also diminishes rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep.{32470}
Brand:CaymanSKU:20003 -Available on backorder
ABD459 is a neutral antagonist of the central cannabinoid 1 (CB1) receptor (Ki = 8.6 nM).{32470} It inhibits food consumption in nonfasted mice without affecting motor activity.{32470} ABD459 reduces active food seeking for 5-6 hours after treatment, with no rebound after washout. ABD459 also diminishes rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep.{32470}
Brand:CaymanSKU:20003 -Available on backorder
ABD459 is a neutral antagonist of the central cannabinoid 1 (CB1) receptor (Ki = 8.6 nM).{32470} It inhibits food consumption in nonfasted mice without affecting motor activity.{32470} ABD459 reduces active food seeking for 5-6 hours after treatment, with no rebound after washout. ABD459 also diminishes rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep.{32470}
Brand:CaymanSKU:20003 -Available on backorder
ABH is an inhibitor of arginase types I and II.{7926} It inhibits arginase activity in homogenized opossum brain, rectum, and internal anal sphincter (Kis = 0.018, 0.026, and 0.05 µM, respectively), indicating arginase II inhibition, and in the liver (Ki = 0.19 µM), indicating arginase I inhibition. It inhibits arginase II in a classical, competitive manner at a pH of 7.5 and in a slow-binding manner at a pH of 9.5 (Kis = 0.25 and 0.31 µM, respectively).{13124} ABH (150 µg, intracavernosal) increases the duration, but not the rigidity, of penile tumescence in male rabbits and increases vaginal blood flow in female rabbits.{11320} It decreases arginase activity in male rat penis and increases intracavernosal pressure in aged rats when approximately 400 µg was consumed via the drinking water daily for 25 days.{47487} ABH also prevents increases in IL-8 levels, neutrophil and goblet cell numbers, and development of right ventricular hypertrophy, as well as reduces airway fibrosis in a guinea pig model of LPS-induced chronic obstructive pulmonary disease (COPD).{47488}
Brand:CaymanSKU:10006862 - 1 mgAvailable on backorder
ABH is an inhibitor of arginase types I and II.{7926} It inhibits arginase activity in homogenized opossum brain, rectum, and internal anal sphincter (Kis = 0.018, 0.026, and 0.05 µM, respectively), indicating arginase II inhibition, and in the liver (Ki = 0.19 µM), indicating arginase I inhibition. It inhibits arginase II in a classical, competitive manner at a pH of 7.5 and in a slow-binding manner at a pH of 9.5 (Kis = 0.25 and 0.31 µM, respectively).{13124} ABH (150 µg, intracavernosal) increases the duration, but not the rigidity, of penile tumescence in male rabbits and increases vaginal blood flow in female rabbits.{11320} It decreases arginase activity in male rat penis and increases intracavernosal pressure in aged rats when approximately 400 µg was consumed via the drinking water daily for 25 days.{47487} ABH also prevents increases in IL-8 levels, neutrophil and goblet cell numbers, and development of right ventricular hypertrophy, as well as reduces airway fibrosis in a guinea pig model of LPS-induced chronic obstructive pulmonary disease (COPD).{47488}
Brand:CaymanSKU:10006862 - 10 mgAvailable on backorder
ABH is an inhibitor of arginase types I and II.{7926} It inhibits arginase activity in homogenized opossum brain, rectum, and internal anal sphincter (Kis = 0.018, 0.026, and 0.05 µM, respectively), indicating arginase II inhibition, and in the liver (Ki = 0.19 µM), indicating arginase I inhibition. It inhibits arginase II in a classical, competitive manner at a pH of 7.5 and in a slow-binding manner at a pH of 9.5 (Kis = 0.25 and 0.31 µM, respectively).{13124} ABH (150 µg, intracavernosal) increases the duration, but not the rigidity, of penile tumescence in male rabbits and increases vaginal blood flow in female rabbits.{11320} It decreases arginase activity in male rat penis and increases intracavernosal pressure in aged rats when approximately 400 µg was consumed via the drinking water daily for 25 days.{47487} ABH also prevents increases in IL-8 levels, neutrophil and goblet cell numbers, and development of right ventricular hypertrophy, as well as reduces airway fibrosis in a guinea pig model of LPS-induced chronic obstructive pulmonary disease (COPD).{47488}
Brand:CaymanSKU:10006862 - 5 mgAvailable on backorder